{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:58:59Z","timestamp":1793059139187,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ucl.2022.09.013","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T16:55:34Z","timestamp":1669049734000},"page":"145-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Evolving Landscape of Viral, Immune, and Molecular Biomarkers in Penile Cancer"],"prefix":"10.1016","volume":"50","author":[{"given":"Alice","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Chahoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ucl.2022.09.013_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.21037\/tau.2017.05.19","article-title":"Updates on the epidemiology and risk factors for penile cancer","volume":"6","author":"Douglawi","year":"2017","journal-title":"Transl Androl Urol"},{"issue":"10 Suppl","key":"10.1016\/j.ucl.2022.09.013_bib2","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.23743","article-title":"Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003","volume":"113","author":"Hernandez","year":"2008","journal-title":"Cancer"},{"issue":"2 Suppl 1","key":"10.1016\/j.ucl.2022.09.013_bib3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.urology.2010.03.003","article-title":"Epidemiology and natural history of penile cancer","volume":"76","author":"Pow-Sang","year":"2010","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2022.09.013_bib4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1590\/S0365-05962011000200014","article-title":"Human papillomavirus infection: etiopathogenesis, molecular biology and clinical manifestations","volume":"86","author":"Leto","year":"2011","journal-title":"An Bras Dermatol"},{"issue":"6","key":"10.1016\/j.ucl.2022.09.013_bib5","first-page":"481","article-title":"Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies","volume":"66","author":"Spiess","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.013_bib6","first-page":"245","article-title":"A\u00a0contemporary review of HPV and penile cancer","volume":"30","author":"Stratton","year":"2016","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.013_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1470-2045(18)30682-X","article-title":"Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis","volume":"20","author":"Olesen","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2022.09.013_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1086\/381395","article-title":"Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men","volume":"189","author":"Weaver","year":"2004","journal-title":"J\u00a0Infect Dis"},{"issue":"8","key":"10.1016\/j.ucl.2022.09.013_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081777","article-title":"Advances in understanding of penile carcinogenesis: the search for actionable targets","volume":"18","author":"Chipollini","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.ucl.2022.09.013_bib10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/17460441.2014.925875","article-title":"Novel targeted therapies for the treatment of penile cancer","volume":"9","author":"Agarwal","year":"2014","journal-title":"Expert Opin Drug Discov"},{"issue":"6","key":"10.1016\/j.ucl.2022.09.013_bib11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","article-title":"The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53","volume":"63","author":"Scheffner","year":"1990","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.013_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/path.1394","article-title":"Evidence for at least three alternative mechanisms targeting the p16INK4A\/cyclin D\/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus","volume":"201","author":"Ferreux","year":"2003","journal-title":"J\u00a0Pathol"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.013_bib13","first-page":"81","article-title":"p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy","volume":"168","author":"Lopes","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2022.09.013_bib14","first-page":"526","article-title":"Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome","volume":"193","author":"Djajadiningrat","year":"2015","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2022.09.013_bib15","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/ijc.21961","article-title":"Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival","volume":"119","author":"Lont","year":"2006","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.ucl.2022.09.013_bib16","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1002\/1097-0142(20010615)91:12<2315::AID-CNCR1263>3.0.CO;2-C","article-title":"Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy","volume":"91","author":"Bezerra","year":"2001","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2022.09.013_bib17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1590\/S1677-5538.IBJU.2013.04.12","article-title":"Human papilloma virus: prevalence, distribution and predictive value to lymphatic metastasis in penile carcinoma","volume":"39","author":"Fonseca","year":"2013","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.ucl.2022.09.013_bib18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12885-015-1268-z","article-title":"The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma","volume":"15","author":"Steinestel","year":"2015","journal-title":"BMC Cancer"},{"issue":"10008","key":"10.1016\/j.ucl.2022.09.013_bib19","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ucl.2022.09.013_bib20","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovic","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2022.09.013_bib21","doi-asserted-by":"crossref","first-page":"107481","DOI":"10.1016\/j.intimp.2021.107481","article-title":"Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients","volume":"94","author":"Aydin","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.013_bib22","doi-asserted-by":"crossref","first-page":"e17517","DOI":"10.1371\/journal.pone.0017517","article-title":"Alternative HER\/PTEN\/Akt pathway activation in HPV positive and negative penile carcinomas","volume":"6","author":"Stankiewicz","year":"2011","journal-title":"PloS one"},{"issue":"12","key":"10.1016\/j.ucl.2022.09.013_bib23","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.humpath.2013.07.012","article-title":"The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases","volume":"44","author":"Chaux","year":"2013","journal-title":"Hum Pathol"},{"issue":"24","key":"10.1016\/j.ucl.2022.09.013_bib24","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-15-1004","article-title":"Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy","volume":"75","author":"McDaniel","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2022.09.013_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1479-5876-11-161","article-title":"Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study","volume":"11","author":"Di Lorenzo","year":"2013","journal-title":"J\u00a0Transl Med"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.013_bib26","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bju.14013","article-title":"First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study","volume":"121","author":"Necchi","year":"2018","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.ucl.2022.09.013_bib27","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3390\/cancers13102323","article-title":"Assessment of PI3K\/mTOR\/AKT pathway elements to serve as biomarkers and therapeutic targets in penile cancer","volume":"13","author":"Thomas","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.ucl.2022.09.013_bib28","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/cancers14071683","article-title":"Value of c-MET and associated signaling elements for predicting outcomes and targeted therapy in penile cancer","volume":"14","author":"Thomas","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ucl.2022.09.013_bib29","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-20-4004","article-title":"Whole-exome sequencing in penile squamous cell carcinoma uncovers novel prognostic categorization and drug targets similar to head and neck squamous cell carcinoma","volume":"27","author":"Chahoud","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2022.09.013_bib30","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3389\/fimmu.2018.01253","article-title":"The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma","volume":"9","author":"Ottenhof","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ucl.2022.09.013_bib31","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s13277-014-2864-2","article-title":"Pathologic and imunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: Fox-P3 expression is an independent predictor of recurrence","volume":"36","author":"Vassallo","year":"2015","journal-title":"Tumour Biol"},{"issue":"10","key":"10.1016\/j.ucl.2022.09.013_bib32","first-page":"3334","article-title":"The immune microenvironment in penile cancer and rationale for immunotherapy","volume":"9","author":"Ahmed","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.ucl.2022.09.013_bib33","first-page":"1147","article-title":"Systematic review and meta-analysis-is there a benefit in using neoadjuvant systemic chemotherapy for locally advanced penile squamous cell carcinoma?","volume":"203","author":"Azizi","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"9","key":"10.1016\/j.ucl.2022.09.013_bib34","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2022.09.013_bib35","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10637-021-01100-x","article-title":"Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial","volume":"39","author":"Hahn","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ucl.2022.09.013_bib36","doi-asserted-by":"crossref","first-page":"615298","DOI":"10.3389\/fonc.2020.615298","article-title":"Case report: two cases of chemotherapy refractory metastatic penile squamous cell carcinoma with extreme durable response to pembrolizumab","volume":"10","author":"Chahoud","year":"2020","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2022.09.013_bib37","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014322000738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014322000738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:56:30Z","timestamp":1758808590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014322000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0094014322000738"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2022.09.013","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolving Landscape of Viral, Immune, and Molecular Biomarkers in Penile Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2022.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}